FDA Labeling Reform Will Trim Adverse Event Section, Temple Says
Executive Summary
FDA's package insert reform initiatives include a thinning out of the adverse event section, CDER Office of Medical Policy Director Robert Temple, MD, told a public workshop on risk management April 10
You may also be interested in...
Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C
Labeling And Liability: FDA Wary Of “Over-Warning,” “Piling On” By Lawyers
Trial lawyers should work with FDA to focus product liability actions on cases where manufacturers appear to be withholding information, Commissioner McClellan suggested during the National Community Pharmacists Association legislative conference May 19 in Washington, D.C
FDA Strategic Plan: Milestones Will Be Unveiled In June
FDA plans to outline milestones for implementing a strategic action plan in a document slated for release by early June